Rani Therapeutics Holdings Inc. Class A Common Stock (RANI)

FairStock Score: 38/100 — MIXED

Key Financials

Strengths

• Conservative balance sheet with debt-to-equity of just 0.10, providing financial flexibility
• Revenue growth of 42.1% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Altman Z-Score of 1.1 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

Rani Therapeutics Holdings Inc. Class A Common Stock is a micro-cap healthcare company valued at $111 million. Revenue stands at $2 million, though the company is currently unprofitable. From a quality standpoint, Rani shows solid Piotroski F-Score of 6/9 and distressed Altman Z-Score of 1.1 warrants caution. On valuation, the stock is 0.3% FCF yield. Growth dynamics show revenue growing at 42.1% and profit growth of -15.2%. Our composite FairStock Score of 38/100 reflects below-average fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

Rani's 42% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. Operational leverage in the business model means incremental revenue growth could disproportionately boost bottom-line profitability.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer